Rodolfo Calixto

Current activity trends and outcomes of hematopoietic cell transplantation: A 2026 report from the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the CIBMTR & SBTMO

Anderson João Simione, Cinthya Corrêa da Silva, Afonso Celso Vigorito, Antônio Vaz de Macedo et autres

The development of the Brazilian Registry of Hematopoietic Cell Transplantation (Registro Brasileiro de Transplantes de Células Hematopoieticas), in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), continues to provide a comprehensive assessment of hematopoietic cell transplantation (HCT) activity …

br, us, Afrique du Sud (code pays fourni par la source)

Comparison of Carmustine-, Lomustine-, and Nitrosourea-Free Conditioning Regimens for Autologous HCT (Auto-HCT) in Lymphoma: Results From the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR)

Abrahão Elias Hallack Neto, Vanderson Rocha, EC Miranda, Fernando B Duarte et autres

None.

br, us (code pays fourni par la source)

Patients with myelodysplastic/myeloproliferative neoplasms have higher rates of relapse following allogeneic hematopoietic cell transplantation compared to those with MDS: A Brazilian SBTMO/CIBMTR registry analysis

Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vanderson Rocha, Vaneuza Araújo Moreira Funke et autres

The Myelodysplastic/Myeloproliferative neoplasm (MDS/MPN) overlap syndromes are a heterogeneous group of rare hematologic malignancies characterized by features of both MDS such as morphologic dysplasia and cytopenias and MPNs including elevated blood counts and often splenomegaly [ 1 ]. These syndromes frequently harbor …

br (code pays fourni par la source)

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hypoplastic Myelodysplastic Syndrome: A Latin American Multicenter Analysis

Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Maria Cristina Martins de Almeida Macedo, Vaneuza Araújo Moreira Funke et autres

BACKGROUND: The hypoplastic myelodysplastic syndromes (MDS-h), a rare subtype accounting for 10% to 15% of patients with myelodysplastic syndromes (MDS), is defined by a reduction of ≤25% bone marrow cellularity, age-adjusted according to the World Health Organization (WHO) 2022 classification. Allogeneic hematopoietic …

br, ar, es (code pays fourni par la source)

Advances and Impact of Risk Stratification in Myelodysplastic Syndromes: Efforts from the Latin American Hematopoietic Cell Transplantation Registry.

Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vaneuza Araújo Moreira Funke, Anderson João Simioni et autres

Background Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative treatment for Myelodysplastic syndromes (MDS). The International Prognostic Scoring System (IPSS), created in 1997, and the revised IPSS (IPSS-R) in 2012 are well-established tools widely used in clinical practice for therapeutic …

Comparative Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic/Myeloproliferative Neoplasms and Other Myelodysplastic Syndromes: Brazilian Sbtmo/CIBMTR Registry Analysis.

Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vanderson Rocha, Vaneuza Araújo Moreira Funke et autres

Hematopoietic cell transplantation outcomes in public centers in Brazil: analysis of the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy, 2012–2024

Anderson João Simione, CA Silva, Nelson Hamerschlak, Afonso Celso Vigorito et autres

This study provides a national overview of hematopoietic cell transplantation (HCT) outcomes in the Brazil’s public healthcare network, using data consolidated in the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy (RBTCH-TC). A total of 5,923 first HCTs performed between 2012 …

br (code pays fourni par la source)

Regional Disparities and Socioeconomic Factors Affecting Outcomes of Hematopoietic Cell Transplantation in Brazil: Insights From the Brazilian Bone Marrow Transplant Map

Giancarlo Fatobene, Carmen Silvia Vieitas Vergueiro, Anderson João Simione, Lívia Mariano et autres

br (code pays fourni par la source)

Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators

Anderson João Simione, Cinthya Corrêa da Silva, Afonso Celso Vigorito, Antônio Vaz de Macedo et autres

Systematic evaluation of hematopoietic cell transplantation (HCT) outcomes is essential to improve clinical practice and meet international quality standards. In Brazil, the partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and …

br, gb, us (code pays fourni par la source)

Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry

Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vaneuza Araújo Moreira Funke, Anderson João Simione et autres

This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988-2023). Of the 441 patients, 70 …

br, ar (code pays fourni par la source)

CURRENT USE AND OUTCOMES OF HEMATOPOIETIC CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2025

Anderson João Simione, Cinthya Corrêa da Silva, Afonso Celso Vigorito, Antônio Vaz de Macedo et autres

The development of the Brazilian Registry of Hematopoietic Cell Transplantation (HCT) in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) continues to provide a comprehensive assessment of the activity and general outcomes of HCT in Brazil. In this …

br, us (code pays fourni par la source)

Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry

Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vaneuza Araújo Moreira Funke, Anderson João Simioni et autres

Introduction Hematopoietic stem cell transplantation (HCT) is the only curative option for patients with myelodysplastic syndrome (MDS). However, many elderly patients are not eligible due to adverse clinical conditions. The objective of this study is to understand the outcomes of allogeneic HCT …

br, uy (code pays fourni par la source)